A Study of Selumetinib in Patients With Kaposi's Sarcoma
Status:
Terminated
Trial end date:
2017-12-20
Target enrollment:
Participant gender:
Summary
Cancer is a leading cause of death in individuals living with human immunodeficiency virus
(HIV), and Kaposi's sarcoma (KS) remains the commonest HIV-associated cancer. KS is caused
when individuals become infected with both HIV and another virus, Human herpesvirus-8
(HHV-8). Laboratory studies have shown that HHV-8 can stimulate biological pathways within KS
lesions which promotes their growth. Selumetinib targets these pathways and may therefore be
a useful new therapy for KS. Phase I of this trial aims to identify the best dose for the use
of selumetinib and investigate the effects of selumetinib treatment on the anti-viral
treatment HIV patients receive to control HIV infection. Phase II of this trial will
investigate how well selumetinib works as a treatment for KS at the best dose determined in
phase I.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sheffield Teaching Hospitals NHS Foundation Trust
Collaborators:
AstraZeneca Cancer Research UK Thermo Fisher Scientific University of Birmingham University of Sheffield